

Research

Open Access

PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study

Norma A Hernández*¹, Elma Correa¹, Esther P Avila¹, Teresa A Vela² and Víctor M Pérez²

Address: ¹Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Mexico City, Mexico and ²Patología Post-Mortem y Tumores Mamaros, Instituto Nacional de Cancerología, Mexico City, Mexico

Email: Norma A Hernández* - normahernandez21@yahoo.com; Elma Correa - elsy15@yahoo.es; Esther P Avila - akane_217@yahoo.com.mx; Teresa A Vela - terezan2002@yahoo.com; Víctor M Pérez - pesv2003@yahoo.com

* Corresponding author

Published: 18 June 2009

Received: 20 January 2009

Journal of Translational Medicine 2009, **7**:47 doi:10.1186/1479-5876-7-47

Accepted: 18 June 2009

This article is available from: <http://www.translational-medicine.com/content/7/1/47>

© 2009 Hernández et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The protease-activated receptor (PAR1) expression is correlated with the degree of invasiveness in cell lines. Nevertheless it has never been directed involved in breast cancer patients progression. The aim of this study was to determine whether PAR1 expression could be used as predictor of metastases and mortality.

Methods: In a cohort of patients with infiltrating ductal carcinoma studied longitudinally since 1996 and until 2007, PAR1 over-expression was assessed by immunoblotting, immunohistochemistry, and flow cytometry. Chi-square and log rank tests were used to determine whether there was a statistical association between PAR1 overexpression and metastases, mortality, and survival. Multivariate analysis was performed including HER1, stage, ER and nodes status to evaluate PAR1 as an independent prognostic factor.

Results: Follow up was 95 months (range: 2–130 months). We assayed PAR1 in a cohort of patients composed of 136 patients; we found PAR1 expression assayed by immunoblotting was selectively associated with high grade patients (50 cases of the study cohort; $P = 0.001$). Twenty-nine of 50 (58%) patients overexpressed PAR1, and 23 of these (46%) developed metastases. HER1, stage, ER and PAR1 overexpression were robustly correlated (Cox regression, $P = 0.002$, $P = 0.024$ and $P = 0.002$ respectively). Twenty-one of the 50 patients (42%) expressed both receptors (PAR1 and HER1 $P = 0.0004$). We also found a statistically significant correlation between PAR1 overexpression and increased mortality ($P = 0.0001$) and development of metastases ($P = 0.0009$).

Conclusion: Our data suggest PAR1 overexpression may be involved in the development of metastases in breast cancer patient and is associated with undifferentiated cellular progression of the tumor. Further studies are needed to understand PAR1 mechanism of action and in a near future assay its potential use as risk factor for metastasis development in high grade breast cancer patients.

Background

Breast cancer is a health problem, specifically in developing countries, where early diagnosis systems are lacking and mortality rates continue to increase. In Mexico up to 25 new cases of breast cancer are diagnosed everyday with mortality rates reaching 15.7 per 100,000 in women under 25 years of age [1,2]. Metastases to bone, lung, liver, and the central nervous system represent the main complication of treatment and also the main cause of death. For example, breast cancer patients with pulmonary metastases have an overall survival rate of 38% and 22% by five and ten years respectively after the initial cancer diagnosis [3,4].

Recent discovery of new factors involved in breast cancer progression *in vitro*, are difficult to translate into diagnostic tools to accurately identify patients at high risk of metastasis. To improve treatment and survival of these patients, a better molecular understanding of the early mechanisms leading to metastases is required [5,6]. The thrombin receptor, protease-activated receptor-1 (PAR1), participates in a variety of biological processes, such as tissue remodelling, inflammation, proliferation and angiogenesis. PAR1 has long been thought to be involved in tumour invasion, metastases associated with melanomas, as well as with cancer of the breast, colon, lung, pancreas, and prostate [7,8]. Although the exact role of PAR1 in tumour cell invasion is not completely understood, it is thought that PAR1 promote detachment and subsequent migration of epithelial cancer cells from and through the basement membrane, a key step in tumour metastases [9-14]. Normal breast epithelial cells do not have the capacity to migrate efficiently in response to chemotactic signals [9-14].

PAR1 is a G protein-coupled receptor. Four different PARs have been identified: PAR1, PAR2, PAR3, and PAR4. PAR1 and PAR3 are activated by thrombin, PAR2 is activated by trypsin or tryptase, and PAR4 is activated by both thrombin and trypsin. PAR1, the prototype member of the PAR family, becomes activated when thrombin cleaves a specific residue sequence (R₄₁-S₄₂) within the receptor's N-terminal extracellular domain. Synthetic peptides that correspond to the first few amino acids of freshly cleaved N terminus (SFLLRN) can function as intramolecular agonists of PAR1. In several experimental models (*in vitro* and *in vivo*), it has been shown that thrombin enhances both tumour cell adhesion to extracellular matrix proteins and the number of lung metastases in animal models [11,12].

In established cancer cell lines, PAR1 expression levels correlate directly with the degree of cancer invasiveness. The human carcinoma breast cancer cell line MDA-MB-231, which is highly invasive, expresses very high levels of

functional PAR1, PAR2, and PAR4. Another human carcinoma breast cancer cell line, MCF-7, which is minimally invasive, expresses only trace amounts of PAR1 and low levels of PAR2 and PAR4. These data are consistent with findings showing that high levels of PAR1 mRNA are found in infiltrating ductal carcinoma, whereas very low amounts are found in normal and premalignant atypical intraductal hyperplasia [13-16].

Despite these advances, the role of PAR1 in breast cancer cell invasion is not completely understood. It has been suggested that thrombin indirectly induces cellular rearrangements by activating PAR1 and transactivating the epidermal growth factor receptor (EGFR and/or HER2) poor prognosis factors for breast cancer patients, which exerts its effects exclusively through intracellular signals. PAR1 has been specifically shown to be involved in the migration and invasiveness of MDA-MB-231 cells via a Gi protein-phosphatidylinositol 3-kinase dependent pathway. Matrix metalloprotease-1 is responsible for activating the invasive functions of PAR1 [[13,14,17] and [18]].

Taken together, these findings prompted us to investigate the role of PAR1 in the development of metastases in breast cancer patients. Our aim was to determine whether PAR1 expression patterns in patients diagnosed with infiltrating ductal carcinoma correlate with long-term clinical outcome. Development of metastases in these patients was used to determine the biologic aggressiveness of the cancer. We believe that cellular factors associated with poor outcome, such as EGFR, HER2 and PAR1 overexpression, if associated with metastases or mortality, could serve to identify patients at high risk to develop metastatic breast cancer. We found significant correlations between PAR1 overexpression and development of metastases and increased mortality. Our data suggest that PAR1 plays an important role in the development of metastases in breast cancer patients. Further studies at the cellular level are essential to clarify the precise role of PAR1 in breast cancer patient's progression.

Methods

Patients

A cohort study was undertaken on a group of 136 female patients from our Institution. They were admitted during first three months of 1996 with a diagnosis of infiltrating ductal carcinoma of the breast; inclusion criteria was limited to women virgin of any treatment elsewhere and confirmed diagnosis of ductal carcinoma; they were followed longitudinally until 2007. After approval from our Institutional board, and with a signed informed consent from each patient, in all cases tissue blocks were taken from the original biopsy used for diagnosis and prior any treatment for PAR1 determination.

The demographic, clinical, and pathological variables examined were age, age at menarche, age at first birth, parity, breastfeeding (considered positive, if were sustained for more than 3 months), clinically and surgical positive axillaries nodes, hormonal status and tumor size. The pathologic size was determined after surgery based upon the greatest dimension of the macroscopic specimen. All patients were infiltrating ductal carcinoma for histological type with a SBR $\geq 5-9$. Classification of the histological type and SBR were made by review of all available histological material by two independent pathologists, who determined the diagnosis and determined tumour grade according to Elston classification [19].

First diagnosis of metastases was noted as the time to first appearance. In all cases diagnosis of metastases was confirmed by X-ray and/or CT-scan for lung metastasis, gamma gram for bone metastases, ultrasonic detection or CT-scan for Liver and CT-scan or magnetic resonance for CNS. Up to four metastases sites were considered; we have not collected tissue samples from all metastasis developed in our cohort patients. Survival was recorded from time of diagnosis to dead. The follow up period began at the date of diagnosis. Patients were followed until death or censored from this analysis at the time of their last visit to our Institution.

Immunoblotting

We used a 50 μm thick sample from each patient, taken from serial paraffin sections. All samples were evaluated by two independent pathologists; if necrosis or positive margins were present the cases were not included in the study. After paraffin removal, tissues were lysed using a collagenase and trypsin buffers over night at 37°C and suspended in lysis buffer (20 mM Tris HCl pH = 7.8, 50 mM NaF, 40 mM $\text{Na}_4\text{P}_2\text{O}_7$, 5 mM MgCl_2 , 10 mM Na_3VO_4 , 1% triton X-100, 0.1% SDS and 5 mM Benzamide) supplemented with 1 $\mu\text{g}/\text{ml}$ each of pepstatin, leupeptin, aprotinin and 2 μM phenyl methyl sulphonyl fluoride (PMSF). After incubation of 20 minutes at 4°C, and removal of cell debris, lysates were centrifuged at 15,000 g for 15 min at 4°C. Clear lysates were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE 12%), blotted into a PVDF membrane (Amersham Life Science) followed by immunoblotting to assess PAR1. As a positive control we also assayed EGFR and HER2 expression, both are well known poor prognostic factor for the outcome of metastatic breast cancer patients, but also known as downstream mediators of PAR1 activation [17,18].

We used a 1:2000 dilution of a mouse monoclonal antibody raised against aminoacids 42–45 of thrombin receptor of human origin (Santa Cruz Bio-Technology). And we also used an anti-EGF receptor mouse monoclonal antibody at same dilution (Upstate) which recognizes the

motif NAEYLR of the EGFR from mouse and human origin. Anti-rabbit polyclonal antibody raised against HER2 receptor from human origin (upstate) was also used at 1:1000 dilution. As a loading control we performed an immunoblot using a 1:2000 dilution of a polyclonal antibody directed against Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) clone V-18 from Santa Cruz Bio-Technology.

Enhanced Chemoluminescence was used to develop the membranes (Amersham Life Science). PVDF membranes were used in all cases (Amersham Life Science). Quantification of the expression of the different mediators was calculated with Aida software and presented as experimental value - control value/control value $\times 100$ where the control value was derived from lysates of cells mock exposed.

In order to validate and give strength to our results we used two different human breast cancer cell lines as positive (MDA-MB-231) or negative (MCF-7) control for PAR1 and EGFR expression as previously reported ([13], data not shown).

Immunohistochemistry (IHC)

IHC staining was carried out for PAR and HER2. We used an antibody that recognizes the N-terminal extracellular loop of human thrombin receptor by immunohistochemistry with formalin-fixed, paraffin-embedded tissues (Sigma); we also used a polyclonal antibody that recognizes amino acids 1243–1255 from the human c-erbB-2/HER2 (Upstate). We compared data obtained by IHC versus that one obtained by western blotting. Method was described previously [20]; briefly the tissues were fixed in 10% buffered formalin, processed and embedded in paraffin. Section 3- μm thick were then cut and dried for 12 h at 37°C. One section from each block was stained with H&E. The sections were de-paraffinised in xylene and rehydrated through graded concentrations of ethanol to distilled water. Incubating the sections in methanol and hydrogen peroxidase for 30 minutes quenched endogenous peroxidase. Immunohistochemical staining was performed by using the ABC system (Bio Genex, CA USA) and DAB as substrate. Blocking serum was applied and incubated for 15 minutes. Then we started the incubation with the primary antibody diluted 1:500 for each antibody. Sections were incubated with the biotinylated secondary antibody and were developed using the peroxidase substrate.

Each staining run included both positive and negative control slides. The positive control slide was prepared from tissue known to contain HER2; the negative control slide was prepared from the same tissue block as the specimen, however instead of using a primary antibody, this one was incubated with an isotype-matched antibody.

HER2 staining was scored utilizing a 3-point scoring system; we considered positive staining, if we observed strong continue and intense staining of the membrane in more than 10% of the cells in the slide. PAR1 were scored positive if any (weak or strong) cytoplasmic and/or membranous invasive carcinoma cell staining was observed in more than 10% of the cells in the slide. Slides were evaluated for two different pathologists.

PAR1 Immunofluorescent staining by Flow Citometry (IF)

To determine PAR1 expression in paraffin-embedded sections from breast cancer patients we used same antibody for western blotting. Tissue samples from the patients were disaggregated into single cell suspensions (collagenase and trypsin 0.25%). Cells (1 × 10⁶) were probed with 1:500 anti-PAR1 dilution of the mouse monoclonal antibody rose against amino acids 42–45 of thrombin receptor of human origin (Thrombin R; ATAP2, Santa Cruz Bio-Technology); and then treated with a goat anti-mouse IgG (H+L) fluorescein conjugate (goat polyclonal). FITC labelled cells were analyzed by flow citometry.

Statistical Analysis

The Chi-square or Fisher tests were used to determine differences between proportions. Overall survival was obtained by the PAR1 estimates by Kaplan-Meier method, and differences between distributions were evaluated by the log-rank test. A Cox Regression was performed including clinical stage, Oestrogen receptor alpha and lymph node status to evaluate PAR1 potential as an independent prognostic factor. P values equal or less than 0.05 was considered statistically significant.

Results

Over expression of PAR1

We assayed PAR1 expression in all samples (136 cases of ductal carcinoma) of the study cohort by IHC, IF and western blotting; however, we found PAR1 receptor expression only in those patients with high grade. Negative results are not shown and we are presenting data from the high grade cases we included in our cohort (50 cases). The median follow-up time of the patients included in the present study was 95 months (range: 2–130 months). Western blot analysis of biopsy samples revealed that 29 of 50 (58%) patients with infiltrating ductal carcinoma of the breast, expressed PAR1 (Figure 1a and 1b, Table 1).

Densitometric quantification of PAR1-immunoreactive bands indicated that 20 of the 29 patients (69%) overexpressed PAR1 by more than 70% (Figure 1a and 1b) of that expressed by a mock exposed invasive breast cancer cell line (previously described in methods, data not shown). Twenty one of 50 (42%) high grade patients did not express PAR1 at all (Table 1 and Figure 1). We also confirmed PAR1 expression in samples from our patients using immunofluorescent staining for PAR1 present in the surface of the cells (Figure 1c), and found 30 patients out of 50 high grade breast cancer patients included in this study (70%) express PAR1; highly significant when compared with the rest of the group (P = 0.0001).

In regard to IHC data, as expected, more samples showed PAR1-immunoreactivity by immunoblotting than the ones assayed by IHC (Figure 1d); we found 25 samples positive for PAR1 expression (50%) by IHC. Nevertheless, all samples showing PAR1-immunoreactivity with IHC were also positive when assayed by Western blotting. Spearman correlation between PAR1 expression measured by IHC versus that measured by immunoblotting was highly significant (P = 0.0005, r = 0.4767). Our analysis was carried out using the more sensitive and quantitative immunoblotting results, but it is important to mention, that all 25 tumor samples positive for PAR1 expression shown different degree of immune reactivity: 48.3% stained lightly, 24.1% moderately and 27.6% strongly. PAR1 expression was found mainly in the entire membrane although some cytoplasmatic staining was also observed (Figure 1d); we found some degree of variation in the staining of PAR1 within the tumor; although we were assaying a biopsy sample of the tumor; we have been able to assayed some tumor samples (from the surgery), initially found PAR1 positive; roughly we found more than 50% of the tumors cells were immune reactive for PAR1 staining; non significant staining was found in the surrounding tumor microenvironment. (Figure 1d) Regarding HER2 expression we found 5% tumors tested were HER2 negative, 38.3% stained weakly, 34.8% moderately and 28.2% strongly.

Correlations between HER2 and EGFR and PAR1 over expression

To determine whether there is an association between HER2, EGFR1 and PAR1 expression, we assessed the

Table 1: PAR1 expression in breast cancer patients

Western blotting PAR1 immunoreactivity	No. of patients* (%)	Patients with metastases†(%)
Positive	29/50 (58%)	23/23 (100%)
Negative	21/50 (42%)	0

*Total number of patients (N_T = 50)

†Number of patients with metastases (N = 23/50 [46%])





Figure 1
PAR1 expression in breast cancer patients. Western blots showing PAR and EGFR expression profiles of tumor biopsy samples from patients with infiltrating ductal carcinoma (Figure 1a and 1b). The blots are representative of three replicate tests. (c) A representative example of immunofluorescent staining of PAR1; Red line: background fluorescence (secondary antibody alone); green line: fluorescent shift attributable to PAR1 expression. Traces shown are representative of one of three independent measurements. (d) A tissue sample exhibiting PAR1 (visualized using $\times 10$ and $\times 40$, objective lens) and HER2 strong membrane immunostaining; also shown: H&E and a negative control sections.

expression of these markers in biopsy tissue obtained from our patients (Figure 1). Twenty-five of 50 (50%) samples expressed EGFR1 and HER2. Densitometry analysis revealed that 23 of the 25 (92%) samples overexpressed EGFR1 and HER2 by more than 80% compared to controls (breast cancer cell lines as previously described; data not shown). Twenty-one of 50 (42%) samples expressed both PAR1 and EGFR1 and HER2. Statistical analysis revealed a significant correlation between PAR1 and EGFR1 overexpression (Fisher exact two-tailed test, $P = 0.0004$; Spearman Rank correlation, $r = 0.5755$, $P = 0.0001$). To evaluate the diagnostic potential of EGFR1 expression in relation to PAR1, we also measured the sensitivity, specificity, and predictive powers of this association. We found a sensitivity value of 0.72 (95% confidence interval: 0.53 to 0.87), a specificity value of 0.81 (0.58 to 0.95), a positive predictive value of 0.84 (0.64 to 0.95), and a negative predictive value of 0.68 (0.46 to 0.85). In summary, if the breast cancer sample expressed EGFR1, it was likely to also express PAR1.

PAR1 over expression and metastases development

Disease progressed rapidly in our study population (Figure 2). Of the 50 patients assessed, 23 (46%) developed metastases, mostly within the first 24 months after receiving their cancer diagnosis. We found a significant association between PAR1 overexpression and metastases: all 23 of these patients overexpressed PAR1 (Table 1, Figure 2). Comparing this group with the group that did not develop metastases and did not overexpress PAR1, Fisher's exact test and a log rank test revealed a highly a reliable difference ($P < 0.0001$ and $P = 0.00009$, respectively). Although 23 of 29 (79%) of the patients overexpressing PAR1 developed metastases during the study, it is notable that 10 (35%) of these patients already had at least one metastasis at the beginning of this study, indicating the advanced clinical status of our patients. We also found a significant correlation between EGFR1 overexpression and metastases development in our patients ($P < 0.0001$, data not shown). Also it was of interest to analyse the distribution of metastases by organ and the order of appearance on a



PAR1 (+) $N_T=29$	At risk	No Events	Median Follow-up (months)
—○— Metastases (-)	6	0	83 (67-107)
—●— Metastases (+)	23	18	11 (1-91)

Figure 2
Kaplan-Meier survival estimates of breast cancer patients overexpressing PAR1: those with and without metastases. The survival of high-grade breast cancer patients overexpressing PAR1 ($N = 29$) is shown as a function of metastases development. The differences between overall survival distributions were statistically significant ($P = 0.0009$).

patient-by-patient basis. We found that 22 of 50 (44%) patients developed their first metastasis in the following locations: 10 of 22 (45%) in extra-axillary lymphatic nodules, 6 of 22 (27%) in bone, 5 of 22 (23%) in lung and 1 of 22 (5%) in liver.


PAR1 overexpression and mortality

Twenty-two of 50 patients (44%) died of their disease. Eighteen (36%) expressed PAR1. That is, of the 29 PAR1-positive patients participating in our study, 18 (62%) died. Fisher exact test analysis revealed a statistically significant link between PAR1 overexpression and increased mortality ($P < 0.0001$). This link was also supported by Kaplan-Meier overall survival analysis (Figure 3). Differences between overall survival distributions were highly significant as determined by a log-rank test ($P = 0.0001$). We also found a significant correlation between EGFR overexpression and mortality ($P < 0.0001$, data not

shown). In addition to examining positive association factors, we also analyzed our group of patients for usual prognostic factors associated with tumour mortality in breast cancer. Tumour size (≥ 5) and presence of pulmonary metastases were significantly correlated, specifically in groups of patients with or without PAR1 over-expression ($P = 0.0004$ and $P = 0.0012$ respectively).

Differences in demographic and clinical variables among PAR1-positive/negative patients

To determine the potential of PAR1 as a useful prognostic factor for breast cancer patients, independent of the prognostic factors for tumour mortality; we compared the demographic, clinical, and pathological characteristics of the 29 PAR1-positive patients to those of the 21 PAR1-negative patients (Table 2). We found no major differences between the two groups regarding age, age at menarche, age at first birth, parity, or breast-feeding.



	At risk	No Events	Median Follow-up (months)
—○— PAR1 (negative)	21	4	101 (67-107)
—●— PAR1 (positive)	29	18	67 (2-107)

Figure 3
Overall Kaplan-Meier survival estimates as a function of PAR1 expression. The overall survival of breast cancer patients is shown according to PAR1 overexpression. The differences between overall survival distributions were statistically significant ($P = 0.0001$).

Moreover, we found no significant differences between the two groups regarding the following clinical and pathological parameters: the number of affected lymphatic axillary nodules (surgically identified [data not shown] or clinically palpable), hormonal status, or tumour diameter.

However, we did find a significant correlation between PAR1 status and cancer invasiveness ($P < 0.05$). The disease of patients with PAR1-positive tumours tended to be more clinically advanced than that of PAR1-negative patients. Of the 29 patients who were over expressing PAR1, 22 (76%) had IIIA-, IIIB-, or IV-stage breast cancer. Only seven of 29 (24%) had I-, IIA-, or IIB-stage cancer. In contrast, of the 21 PAR1-negative patients, only six (29%) had IIIA-stage or greater cancer, whereas 15 (71%) had IIB-stage or lower cancer.

We also performed a multivariate analysis including stage, estrogen receptor (alpha), and lymph node status to evaluate PAR1 as an independent prognostic factor. Although the small size of our cohort of patients, Cox regression demonstrates highly significant p values for EGFR ($P = 0.002$), stage ($P = 0.024$), and absence of estrogen receptor ($P = 0.002$). We did not find any significance for lymph node status ($P = 0.441$).

Therapeutic treatment received by our patients

Our institution offers a diverse regimen of breast cancer treatments that can impact disease outcome, particularly the outcome of those in advanced stages of the cancer. To determine whether our treatment schemes had contrib-

uted to our finding that PAR1 status affects the clinical status of breast cancer, we grouped our patients by the treatment they received and carried out statistical analyses. All 50 high grade cases underwent radical resection of the tumor. The patients received both systemic and local therapy: systemic chemotherapy (mainly combinations of doxorubicin [Adriamycin®] and cycloheximide) and/or hormonotherapy (taxanes); and local chemotherapy and/or radiotherapy before surgery). PAR1-positive and PAR1-negative patients were treated similarly. There were no significant differences in the types of therapy received by PAR1-positive and PAR1-negative patients.

Discussion

In the present study, we demonstrated that PAR1 overexpression assayed by immunoblotting is associated with an increased risk of metastases development and mortality in patients with breast cancer (Table 1, Figures 1, 2, 3). All patients with metastases overexpressed PAR1 (Figure 2). Moreover, the majority of our PAR1-overexpressing patients died during the course of this study (Figure 3). Our data suggest PAR1 plays an important role in the mechanisms underlying the development of metastases [[8,10], and [14]]. Our findings are consistent with previous findings showing mRNA of PAR1 is expressed in primary breast cancer tissue; mediates the invasive potential of certain breast cancer cell lines [13,15], and that it is involved in the tumour progression [16].

We also found a significant correlation between the co-overexpression of PAR1, EGFR1 and increased risk for metastases (Figure 1 and 2). This link is not surprising, since EGFR is a very well known poor prognostic factor in breast cancer patients [[8,21] and [22]]. Furthermore it had been shown that proteolytic activation of PAR1 by thrombin induces persistent transactivation of EGFR and ErbB2/HER2 in invasive breast carcinoma (23). Selectivity of PAR1 expression in tumor samples, its invasive potential shown in breast cancer cell lines, and the important role played by EGFR/HER2 as downstream transactivators of PAR1, indeed explains the positive correlation we found, between the expression of prognostic factors conveying poor disease outcome and poor tumour differentiation [15,16,24]. Furthermore in our experience, PAR1 it is not expressed at all or expressed at very low levels in tumor samples from breast cancer patients with SBR = 8 as previously assayed in our laboratory (data not shown). To treat high risk population effectively and as early as possible during the course of their disease, we need a better understanding of the mechanisms underlying tumour progression.

Although the significant correlation between PAR1 overexpression and increased mortality may be just a consequence of tumour progression translated as the

Table 2: Distribution of demographic, clinical, and pathological variables of breast cancer patients as a function of PAR1 expression

Variable	PAR1*(+)	PAR1*(-)
Age (years)	50 (23–77)	47 (31–58)
Age at menarche (years)	13 (11–16)	13 (12–15)
Age at first birth (years)	23 (18–34)	22 (19–33)
Parity	3 (0–12)	2 (0–8)
Breastfeeding (>3 months)	15/29 (52%)	14/21 (67%)
Clinically positive axillary nodes	19/29 (66%)	15/21 (71%)
Hormonal status†		
Pre-menopausal	15/29 (52%)	11/21 (52%)
Post-menopausal	14/29 (48%)	10/21 (48%)
Tumour diameter (cm)	7 (2–25)	6 (2–8)
ER‡ (+)	15/29 (52%)	10/21 (48%)
Total (N _T = 50)	29	21

*Median (range or percentage) unless specified.

†Circulating estrogen and progesterone levels

‡Estrogen receptor status

establishment of metastases (Figures 2 and 3), this link is still significant. It is well documented that visceral (lung, liver) or CNS metastases result in the poorest prognostic outcome for any given cancer [3,25-27]. PAR1 has been shown to mediate the formation of pulmonary metastases in animal models of cancer [12]. In the present study, we found a very robust, significant correlation between PAR1 overexpression and the formation of pulmonary metastases. Most of the patients developed their first metastases within the first 24 months of being diagnosed; and the site of these metastases tended to affect extra-axillary nodules. Secondary metastatic sites were bone, lung, liver, and CNS. Taken together, these findings implicate PAR1 as a potential marker for aggressive cancer.

Our findings strongly implicate PAR1 as a prominent factor involved in tumour progression in breast cancer, thereby supporting its use as potential prognostic factor for invasive breast cancer. Indeed, we found that the clinical status or stage of breast cancer in our patients was correlated with PAR1 overexpression: patients overexpressing PAR1 in biopsy samples had more advanced disease than did patients not expressing PAR1. This may have very important implications at the cellular level [28,29], since PAR1 may be first expressed in high-grade patients when tumour progression is initiated. Thus, regular tracking of PAR1 status may be useful to identify early on breast cancer patients at high risk for metastases.

Furthermore we have demonstrated despite the small size of our cohort of patients, the multivariate analysis we performed, shown highly significant p values for EGFR ($P = 0.002$), stage ($P = 0.024$), and absence of estrogen receptor ($P = 0.002$). Our data strongly suggest PAR1 may be an independent prognostic factor for breast cancer patients. Although our sample of patients was very small, we are confident that PAR1 is an equally accurate prognostic factor for metastases and mortality as are EGFR and HER2 [21,22,24], since comparison of PAR1-positive and PAR1-negative patients revealed no significant differences in the main prognostic parameters typically considered in breast cancer (e.g., age, tumour diameter, hormonal status, etc).

Although treatments were diverse, we analysed this factor and found no remarkable differences between treatment types given to patients who showed PAR1 overexpression and those who did not. Our data identifies PAR1 as a potential prognostic factor for infiltrating ductal carcinoma. Its consistent involvement in the progression of breast cancer makes it an ideal prognostic tool only assayed in cell lines [30,31]. However, because our findings were based on a small sample of patients, the utility of PAR1 as a prognostic tool must be further assessed in a larger population of breast cancer patients, preferably through prospective studies. We are currently conducting

further research to determine whether PAR1 can be used as an independent prognostic factor of these kinds of metastases in breast cancer patients with infiltrating ductal carcinoma. If our hypothesis about PAR1 is correct, the determination of PAR1 status can aid physicians in providing better follow-up therapy for these patients. Those at high risk for metastases can be identified early, allowing enough time for additional chemotherapy or surgical resection of metastases with the aim of achieving long-term survival or a longer disease-free period following surgical resection. This would improve the overall survival of high-grade breast cancer patients.

Conclusion

Our data suggest PAR1 is involved in the development of metastases; showing a great potential as predictor of metastases and mortality in high grade breast cancer patients. Proteases have been implicated in tumor progression but PAR1 may be a good example of protease effectors implicated in tumour invasion and metastasis development and in a near future, PAR1 could become an ideal candidate for assessing new targets for drugs in the early diagnosis and treatment of metastasis in breast cancer patients.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors (NAH, EC, EPA, TAV, VMP) had read and approved the final manuscript

NAH has made substantial contributions to the conceptions, design, analysis and interpretation of the data; she also help in the experimental performance of PAR1 detection and has been involved in drafting the manuscript. EC has made selection of the patient's cohort and reviewed all patient's charts, she also has made substantial contributions to the analysis and interpretation of the data. EPA has been involved in PAR1 detection (WB, IF and IHC), and has been participated actively in the analysis and interpretation of the data. TAV has been involved in the analysis of the immunohistochemistry data, and help with the interpretation of the data. VMP Also have been involved in the analysis and interpretation of the immunohistochemistry data

Acknowledgements

This work was supported by CONACyT (Salud-CO1-03 and Salud-2008-I-CO1-87152). We thank Margarita Alvarez for technical support processing paraffin samples and Alejandro Cabrera for invaluable help using Stata program.

References

1. Bray F, Ferlay J, Pisan P, Parkin DM: **Global Cancer Statistics.** *Cancer J Clin* 2002, **55**:74-108.

2. Registro Histopatológico de Neoplasias Malignas. Dirección General de Epidemiología, Secretaría de Salud: **Compendio de Cáncer 2002: Mortalidad y Morbilidad.**
3. Friedel G, Pastorino U, Ginsberg RJ, Goldstraw P, Johnston M, Pass H: **International Registry of Lung metastases Results of lung metatarsectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of lung metastases.** *Eur J Cardio-Thoracic Surg* 2002, **22**:335-344.
4. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding YE, Hortobagyi GN, Bedrosian I, Knickerbocker Ch, Toyofuku W, Lowe M, Herliczek TW, Bacus S: **Cyclin E and Survival in patients with breast cancer.** *N Eng J Med* 2002, **347**:1566-1574.
5. Glondou M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M: **Down regulation of cathepsin-D in primary breast cancer has been associated with rapid development of clinical metastasis.** *Oncogene* 2002, **21**:5127-5134.
6. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J: **TGF beta signalling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.** *Proc Natl Acad Sci USA* 2003, **100**:8430-8435.
7. Bar-Shavit R, Benezra M, Sabbah V, Bode W, Vlodavsky I: **Thrombin as a multifunctional protein: induction of cell adhesion and proliferation.** *Am J Respir Cell Mol Biol* 1992, **6**(2):123-130.
8. Bangham J: **Moving PARts.** *Nat Rev Cancer* 2005, **5**:247.
9. Henrikson KP, Salazar SL, Fenton JW II, Pentecost BT: **Role of thrombin receptor in breast cancer invasiveness.** *Br J Cancer* 1999, **79**:401-406.
10. Arribas J: **Matrix metalloprotease and tumor invasion.** *N Eng J Med* 2005, **352**:2020-2021.
11. Coughlin SR: **Thrombin signaling and protease-activated receptor.** *Nature* 2000, **407**:258-264.
12. Nierodzik ML, Chen K, Takeshita K, Huang LJ, Feng XS, D'Andrea MR, Andrade-Gordon P, Karparkin S: **Protease-activated receptor 1 PAR1 is required and rate limiting for thrombin enhanced experimental pulmonary metastases.** *Blood* 1998, **92**:3694-3700.
13. Kamath L, Meydani A, Foss F, Kuliopulos A: **Signaling from Protease-activated receptors-1 inhibits migration and invasion of breast cancer cells.** *Cancer Res* 2001, **61**:5933-5940.
14. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A: **PAR1 is a matrix metalloprotease receptor that promotes invasion and tumorigenesis of breast cancer cells.** *Cell* 2005, **120**:303-313.
15. Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P, Bar-Shavit R: **Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha v beta 5 integrin.** *J Biol Chem* 2001, **276**:10952-62.
16. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P: **Differential expression of protease activated receptors-1 and -2 in stromal fibroblasts of normal benign and malignant human tissues.** *Am J Pathol* 2001, **158**:2031-2041.
17. Luttrell LM, Daaka Y, Lefkowitz RJ: **Regulation of tyrosine kinase cascades by G-protein coupled receptors.** *Current Opinion Cell Biol* 1999, **11**:177-183.
18. Knowlden JM, Gee JM, Robertson JF, Ellis IO, Nicholson RI: **A possible divergent role of oestrogen receptor α and β subtypes in clinical breast cancer.** *Int J Cancer* 2000, **89**:209-212.
19. Elston W, Ellis IO: **Pathological prognostic factors in breast cancer. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up.** *Histopathol* 1991, **19**:403-410.
20. Skliris GP, Carder PJ, Lansdown MR, Speirs V: **Immunohistochemical detection of ER beta in breast cancer: towards more detailed receptor profiling?** *Br J Cancer* 2001, **84**:1095-1098.
21. Dowell JE, Minna JD: **Chasing mutations in the epidermal growth factor in lung cancer.** *N Engl J Med.* 2005, **352**(8):830-832.
22. Ranson M: **Epidermal growth factor receptor tyrosine kinase inhibitors.** *Br J Cancer* 2004, **90**:2250-2255.
23. Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J: **Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.** *Oncogene* 2008, **27**:4434-4445.
24. Fuqua SAV, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred C: **Estrogen receptor beta protein in human breast cancer: Correlation with clinical parameters.** *Cancer Res* 2003, **63**:2434-2439.
25. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegelé P, Eber M, Ghnassia JP: **Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II α status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.** *Eur J Cancer* 2004, **40**:205-211.
26. Atalay G, Biganzoli F, Renard F, Paridaens R, Cufer : **Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective randomized metastatic breast cancer trials.** *Eur J Cancer.* 2005, **39**(17):2439-2449.
27. Roodman GD: **Mechanisms of bone metastases.** *N Eng J Med* 2004, **350**:1655-1664.
28. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A: **Activation and inhibition of G-protein-coupled receptors by cell-penetrating membrane-tethered peptides.** *Proc Natl Acad Sci USA* 2002, **99**:643-648.
29. Seeley J, Covic L, Jaqcques SL, Sudmeier J, Baleja JD, Kuliopulos A: **Structural basis for thrombin activation of a protease-activated receptor: Inhibition of intramolecular liganding.** *Chem Biol* 2003, **10**:1033-1041.
30. Morris DR, Yu D, Ricks TK, Gullapalli A, Wolfe BL, Trejo J: **Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration and invasion of breast cancer cells.** *Cancer Res* 2006, **66**:307-14.
31. Arora P, Ricks TK, Trejo J: **Protease-activated receptor signaling endocytic sorting and dysregulation in cancer.** *J Cell Sci* 2007, **120**:921-928.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

